Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) with at least 3 months' symptom duration and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA and symptom duration of less than 5 years prior to the participation of this study~* Active disease at Screening as defined by~  * Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥ 2.1~ * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4~ * Spinal pain \> 4 on a 0 to 10 Numerical Rating Scale (NRS) (from BASDAI Item 2)~ * for modified New York (mNY) -negative subjects only: C-reactive Protein (CRP) \> upper limit of normal (ULN) and/or current evidence for sacroiliitis on the Screening Magnetic Resonance Imaging (MRI)~* Inadequate response to, or contraindication to, or intolerant to at least 2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)~Exclusion Criteria:~* Presence of total Spinal Ankylosis ('bamboo spine')~* Diagnosis of any other Inflammatory Arthritis~* Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)~* Exposure to more than 1 TNF-antagonist or primary failure to TNF antagonist therapy~* History of or current chronic or recurrent infections~* High risk of infection~* Recent live vaccination~* Concurrent malignancy or a history of malignancy~* Class III or IV congestive heart failure - New York Heart Association (NYHA)~* Demyelinating disease of the central nervous system~* Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product~* Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Open-label Certolizumab Pegol (Type: OTHER): Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
- Double-blind Certolizumab Pegol 200 mg Q2W (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
- Double-blind Certolizumab Pegol 200 mg Q4W (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind.
- Placebo (Type: PLACEBO_COMPARATOR): One placebo injection is administered every 2 weeks from Week 48 onwards.
- Placebo to CZP 200 mg Q2W escape (Type: OTHER): Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
- CZP 200 mg Q4W to CZP 200 mg Q2W escape (Type: OTHER): Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
- CZP 200 mg Q2W to CZP 200 mg Q2W escape (Type: OTHER): Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).